Compounded Semaglutide Linked to Deaths: What You Need to Know

Wednesday, 6 November 2024, 11:20

Compounded semaglutide has been linked to over 100 hospitalizations and at least 10 deaths, as highlighted by Novo Nordisk's CEO. The safety of compounded medications raises serious concerns, given their lack of FDA regulation. Patients are urged to understand the potential dangers of these products.
Cnn
Compounded Semaglutide Linked to Deaths: What You Need to Know

Understanding Compounded Semaglutide Risks

Compounded semaglutide, an active ingredient in popular diabetes and obesity medications, has been reported to cause significant health risks. Novo Nordisk CEO Lars Fruergaard Jorgensen expressed serious concern regarding the compounded version of the medication, noting that they are not FDA-approved.

Health Concerns and Adverse Events

  • Linked to over 100 hospitalizations.
  • Associated with 10 reported deaths.
  • Reported issues include dosing errors and counterfeit products.

The FDA emphasizes that compounded drugs lack rigorous regulatory oversight.

Current Status and Future Implications

With semaglutide still on the FDA's shortage list, the compounded versions may continue to pose a risk. Novo Nordisk is working with the FDA to address these concerns, emphasizing the health of patients as a priority.


This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.


Related posts


Newsletter

Subscribe to our newsletter for the most accurate and current medical news. Stay updated and deepen your understanding of medical advancements effortlessly.

Subscribe